approval
saveGAZYVA (OBINUTUZUMAB) — FDA approval
community read0 votes
Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalDec 17, 2025 · 287d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalOct 17, 2025 · 348d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalJul 27, 2022 · 1526d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalJul 12, 2022 · 1541d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalFeb 14, 2022 · 1689d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalMar 27, 2020 · 2378d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalNov 16, 2017 · 3240d ago
- approvalGAZYVA (OBINUTUZUMAB) — FDA approvalNov 16, 2017 · 3240d ago
same company · ±60 days · 6
- approvalobinutuzumab: GAZYVA (OBINUTUZUMAB) — FDA approvalOct 17, 2025
- approvalglofitamab: COLUMVI (GLOFITAMAB-GXBM) — FDA approvalOct 27, 2025
- approvalatezolizumab: TECENTRIQ (ATEZOLIZUMAB) — FDA approvalOct 2, 2025
- approval(atezolizumab + hyaluronidase (human recombinant)): TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approvalOct 2, 2025
- approvalinavolisib: ITOVEBI (INAVOLISIB) — FDA approvalSep 25, 2025
- approval(atezolizumab + hyaluronidase (human recombinant)): TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approvalNov 17, 2025
comments(0)
5-min edit window · permanent after that